quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:05:41·13d
SECFiling
Bausch + Lomb Corporation logo

SEC Form DEF 14A filed by Bausch + Lomb Corporation

BLCO· Bausch + Lomb Corporation
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • BLCO
    Bausch + Lomb Corporation
    Health Care

Recent analyst ratings

  • Jan 5UpdateEvercore ISI$18.00
  • Dec 11UpdateCitigroup$20.00
  • Dec 2UpdateMorgan Stanley$21.00
  • Oct 1UpdateGoldman$16.00
  • May 2UpdateH.C. Wainwright$15.00
  • Mar 28UpdateWells Fargo$15.00

Related

  • PR20h
    Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration
  • PR1d
    Bausch + Lomb Releases 2025 Sustainability Impact Report
  • PR7d
    Bausch + Lomb Reports Nearly 725,000 Pounds of Contact Lens, Lens Care and Eye Care Materials Collected and Recycled Through ONE By ONE Recycling Program
  • PR15d
    Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced Update
  • PR16d
    Bausch + Lomb Launches Preloaded enVista Envy™ Full Range of Vision Intraocular Lenses in Europe
  • PR17d
    Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting
  • PR24d
    Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29
  • PR31d
    Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022